Lilly’s triple agonist posts strongest weight loss data yet, unusual skin side effect also reported

One of the most closely watched obesity assets in the clinic, Lilly’s triple-G agonist retatrutide, caused patients with obesity and knee osteoarthritis to lose an average of 23.7% of their body weight at around 16 ...